Twitter Facebook LinkedIn YouTube

Feature company - Advanced Proteome Therapeutics developing superior drug delivery

Video Platform Video Management Video Solutions Video Player

The company, through its Boston-based subsidiary, Advanced Proteome Therapeutics Inc., has developed a proprietary approach for streamlining the production and targeted delivery of anti-cancer drugs to cancerous tumors.

Additional Information:

Company: Advanced Proteome Therapeutics Corporation
Website: http://www.AdvancedProteome.com
Stock Symbol: TSXV: APC
Date Published: Mar 16, 2020
Transcript: Available

Video Transcript:

I’m Fiona Forbes for Investmentpitch Media

Today’s feature company is Advanced Proteome Therapeutics Corporation.

The company, through its Boston-based subsidiary, Advanced Proteome Therapeutics Inc., has developed a proprietary approach for streamlining the production and targeted delivery of anti-cancer drugs to cancerous tumors.

The benefit of targeted therapies, such as Advanced Proteome’s approach, is their ability to home in on cancer cells, while sparing healthy cells, thereby avoiding the nasty side effects of traditional chemotherapeutics.

The proprietary process is versatile and exploits universal features of antibodies, thus simplifying and standardizing, as well as accelerating the process of creating new antibody-drug conjugates that are expected to be easier to produce and to exhibit greater potency, higher specificity and lower toxicity than current therapies.

Because of the benefits of the company’s innovative approach over traditional approaches, it expects to profoundly impact the markets for anti-cancer therapeutics.

Through academic and industrial partnerships, the company has established discovery proof of concept for its antibody drug conjugate or “ADC” and a discovery stage product pipeline, including proprietary antibodies and payloads.

The company will either partner to further establish discovery proof of concept or take proprietary product candidates into the clinic, as appropriate.

In February, the company’s subsidiary was engaged by a promising biotechnology company, based in Chicago, with a lab in Boston, that is seeking to develop an antibody drug conjugate or ADC, utilizing their proprietary antibody.

The preliminary phase will involve pilot testing Advanced Proteome’s site specific conjugation technology with the Biotech’s lead antibody in both in vitro and in vivo models.

Testing will characterize ADC constructs, measure binding affinity and potency in vitro cell models, followed by in vivo testing in murine cancer models to demonstrate ADC construct activity.

At the time of the announcement, Paul Woodward, CEO, stated: “The Company is excited by this project, not only for the tremendous economic benefits that a successful ADC would provide, but also, that this represents another successful step in APTI’s near term business model, and will lead to more data and an enhancement in the Company’s visibility. We believe that our technology represents the new gold standard of conjugation technology and will enable the creation of safer and more efficacious ADC therapeutics for patients; something that only more data can prove to the market.”

The company is currently raising up $500,000 from a non-brokered private placement of up to approximately 8.3 million units priced at $0.06 per unit.

Each unit consists of one share and one warrant, with the warrant exercisable at $0.10 for 18 months.

The company plans to use the funds for research and development of the company’s site-selective linker technology and for general working capital.

The shares are currently trading at $0.06.

For more information, please visit the company’s website www.AdvancedProteome.com, contact Paul Woodward, President & CEO, at 604-690-3797 or for Investor Relations, contact Bill Dickie, at 617-358-7823 or email bill.dickie@AdvancedProteome.com

I’m Fiona Forbes for Investmentpitch Media